Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

BACKGROUND: Everolimus (RAD001) is an orally administered mTOR inhibitor that is well known for its antitumor efficacy and that has been approved for the treatment of several solid tumors, including renal cell carcinoma. In gastric cancer (GC), despite previous preclinical and phase I/II studies sug...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Ji Hyun, Ryu, Min-Hee, Park, Young Soo, Park, Sook Ryun, Na, Young-Soon, Rhoo, Baek-Yeol, Kang, Yoon-Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374284/
https://www.ncbi.nlm.nih.gov/pubmed/25886409
http://dx.doi.org/10.1186/s12885-015-1139-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374284/
https://www.ncbi.nlm.nih.gov/pubmed/25886409
http://dx.doi.org/10.1186/s12885-015-1139-7

Ejemplares similares